Showing 6411-6420 of 7424 results for "".
- Allergan Again Unanimously Rejects Valeant's Revised Unsolicited Proposalhttps://practicaldermatology.com/news/20140610-allergan_again_unanimously_rejects_valeants_revised_unsolicited_proposal/2459212/Allergan has once again rejected the revised unsolicited proposal from Valeant and Pershing Square Capital Management, setting the stage for a lengthy hostile takeover battle. Allergan announced Tuesday that its board of directors, after consulting with its independent financial and legal advisors
- Allergan: Business As Usual Following New Valeant Offerhttps://practicaldermatology.com/news/20140606-allergan_business_as_usual_following_new_valeant_offer/2459215/At Allergan, executives say it is business as usual, even as the board reviews a hefty new offer from Valeant. Valeant last Friday increased its offer to Allergan by $14 per share, “subject to prompt good-faith discussions on a merger agreement.” The new bid values Allergan at about $180 a share and
- Cosmetic Surgery Forum Unveils 2014 Agendahttps://practicaldermatology.com/news/20140606-cosmetic_surgery_forum_unveils_2014_agenda/2459216/The agenda for the 2014 Cosmetic Surgery Forum was recently unveiled. The meeting will take place from December 3 through December 6 at the Palazzo Casino and Resort in Las Vegas, NV. Under course director Joel Schlessinger, MD, this year's meeting will include sessions on cosmetic treatments for me
- Ichthyosis Patient Raising Awareness, Funds with Hikehttps://practicaldermatology.com/news/20140531-ichthyosis_patient_raising_awareness_funds_with_hike/2459223/To raise awareness of ichthysosis and funds for research, Brian Gass of St. Louis is hiking the Pacific Crest Trail – 2,600 miles from Mexico to Canada, crossing the Sierras, over about 110 days. The 21-year-old college student has the rare genetic skin disease, as do three siblings. The experienced
- FDA to Require Warnings on Sunlamp Productshttps://practicaldermatology.com/news/20140530-fda_to_require_warnings_on_sunlamp_products/2459227/The FDA issued a final order reclassifying sunlamp products and ultraviolet (UV) lamps intended for use in sunlamp products from low-risk (class I) to moderate-risk (class II) devices. The order also requires that sunlamp products carry a visible black-box warning on the device
- Allergan Physician Customers Voice Strong Support Following Allergan's Rejection of Unsolicited Proposal to Acquire Companyhttps://practicaldermatology.com/news/20140521-allergan_physician_customers_voice_strong_support_following_allergans_rejection_of_unsolicited_proposal_to_acquire_company/2459232/Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company") today announced that it has received a strong outpouring of support from its physician customers, their nurses and office staff members, as well as from patient advocacy groups and medical associations, following the Company's rejection of Val
- Clinical Trial Finds New Cream Diminishes Symptoms of Psoriasis, Eczemahttps://practicaldermatology.com/news/20140516-clinical_trial_finds_new_cream_diminishes_symptoms_of_psoriasis_eczema/2459237/Findings from an independent study indicate that the antioxidant-based Psorzema Crème formula from derma e® diminishes symptoms of eczema and psoriasis. In an eight-week study, symptomatic participants used Psorzema® Crème, all of whom showed significant improvement in dryness and flak
- Provectus Biopharmaceuticals, Inc.'s Common Shares Begin Trading on NYSEhttps://practicaldermatology.com/news/20140516-provectus_biopharmaceuticals_incs_common_shares_begin_trading_on_nyse/2459239/Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced that its shares will begin trading on the NYSE MKT today, Friday, May 16, 2014. The company's ticker symbol will remain “PVCT” but it will withdraw
- Aldeyra Therapeutics' Lead Candidate NS2 Shows Novel Approach to Treating Dry Skin, Eye Diseaseshttps://practicaldermatology.com/news/20140512-aldeyra_therapeutics_lead_candidate_ns2_shows_novel_approach_to_treating_dry_skin_eye_diseases/2459242/Aldeyra Therapeutics' lead candidate NS2 decreases aldehyde levels in dry skin and eye models, according to data to be presented as an abstract poster at the Society for Investigative Dermatology (SID) 2014 Annual Meeting, in Albuquerque, NM. The study found that topical applicat
- The American Society for Dermatologic Surgery Accreditation Program Applications Due June 15https://practicaldermatology.com/news/20140428-the_american_society_for_dermatologic_surgery_accreditation_program_applications_due_june_15/2459252/Dermatology programs and practices trying to start a fellowship program have until June 15 to apply for accreditation cosmetic program. The program focuses on six topics: patient care, medical knowledge, practice-based learning, interpersonal skills, professionalism, and system-based practice.